Cytosorbents Corporation
CTSO
Rank in Stocks
#26786
Cytosorbents Corporation specializes in creating and bringing to market... Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.
Share Price
$5.83
Last synced: 2026-11-09
Market Cap
$18.37M
Change (1 day)
21.46%
Change (1 year)
735.36%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Cytosorbents Corporation (CTSO)
Category
Healthcare
Operating Margin for Cytosorbents Corporation (CTSO)
Operating Margin as of November 2026 TTM: -33.37%
According to Cytosorbents Corporation's latest financial reports, its current operating margin (TTM) is -33.37%. At the end of 2025 the company had an operating margin of -38.42%.
Operating Margin history for Cytosorbents Corporation from 2005 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -33.37% | -13.14% |
| 2025 | -38.42% | -18.53% |
| 2024 | -47.16% | -54.12% |
| 2023 | -102.78% | 13.11% |
| 2022 | -90.87% | 60.24% |
| 2021 | -56.71% | 115.71% |
| 2020 | -26.29% | -68.45% |
| 2019 | -83.34% | 8.30% |
| 2018 | -76.95% | 4.62% |
| 2017 | -73.55% | -47.48% |
| 2016 | -140.04% | -38.95% |
| 2015 | -229.39% | -0.89% |
| 2014 | -231.45% | -59.64% |
| 2013 | -573.53% | -75.10% |
| 2012 | -2,303.06% | -81.27% |
| 2011 | -12,297.71% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | 0.00% |
| 2006 | 0.00% | -100.00% |
| 2005 | -800.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 15.24% | -100.46% |
US
|
|
| 18.08% | -100.54% |
IE
|
|
| 21.25% | -100.64% |
US
|
|
| 21.05% | -100.63% |
US
|
|
| 28.09% | -100.84% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Cytosorbents Corporation's operating margin
What is Cytosorbents Corporation's operating margin?
Cytosorbents Corporation's operating margin is -33.37%, as of Nov 2026.
What was Cytosorbents Corporation's operating margin in 2025?
In 2025, Cytosorbents Corporation's operating margin was -38.42%, compared with -47.16% in 2024.
How has Cytosorbents Corporation's operating margin changed since 2020?
From 2020 to 2025, Cytosorbents Corporation's operating margin was highest in 2020 (-26.29%) and lowest in 2023 (-102.78%).
How does Cytosorbents Corporation's operating margin compare with similar companies?
Cytosorbents Corporation's operating margin (-33.37%) is lower than that of all 5 similar companies listed above. The highest among them is Edwards Lifesciences Corporation, with 28.09%.